Argenica Therapeutics (ASX:AGN)

Developing novel neuroprotective therapeutics to reduce brain damage after stroke.

About Us

A clinical stage drug development company developing novel therapeutics for stroke and other types of brain injuries, which are developing a "best in class" novel neuroprotective therapeutic.

Company Overview

There is currently a large unmet need for a safe, early intervention therapeutic that provides protection to brain cells immediately following a stroke, until the underlying cause of stroke can be diagnosed and alleviated.

It is Argenica's mission to provide a solution for this unmet need. Their aim is for ARG-007 to be administered by first responders in the field to provide neuroprotective treatment prior to a patient’s arrival at the hospital which will result in improved patient outcomes.

Argenica Therapeutics

Follow Argenica Therapeutics

By submitting your information below you can keep up to date with their relevant news and announcements.

Fields marked with * are required.